Kirurgian vastuualue

Julkaisut 2015
Publications 2015

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.


1 Amin AL et al. Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.
2 Amin AL Olama A et al. Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci.
3 Annala M et al. Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer.
4 Auvinen A, Tammela T. Mitä lääkärin ja potilaan tulee tietää eturauhassyövän seulonnasta?
5 Auvinen A, Tammela T. Mitä lääkärin tulee tietää eturauhassyövän seulonnasta?
6 Buzzoni C et al. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.
7 Cartwright R et al. Systematic review and metaanalysis of genetic association studies of urinary symptoms and prolapse in women.
8 Davies N et al. The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium.
9 Fischer D et al. MiRNA Profiles in Lymphoblastoid Cell Lines of Finnish Prostate Cancer Families.
10 Hakala T. Differentiated Thyroid Cancer: Diagnostics, prognostic factors and long-term outcome.
11 Heijnsdijk E et al. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
12 Hernesniemi J et al. Predicting sudden cardiac death using common genetic risk variants for coronary artery disease.
13 Huovinen S et al. Differential Isoform Expression and Selective Muscle Involvement in Muscular Dystrophies.
14 Järvinen R et al. Long-term Outcome of Patients with Frequently Recurrent Non-muscle-invasive Bladder Carcinoma Treated with One Perioperative Plus Four Weekly Instillations of Mitomycin C Followed by Monthly Bacillus Calmette-Guérin (BCG) etc.
15 Järvinen T et al. BMJ CONFIDENTIAL CLARE TAYLOR: ten minutes is not enougt Authors´reply to Lee and colleagues.
16 Kaapu K et al. Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study.
17 Kaartinen IS et al. Reconstruction of the pelvic floor and the vagina after total pelvic exenteration using the transverse musculocutaneous gracilis flap.
18 Kallio J. Paikallisen munuaissyövän seuranta.
19 Kaukoniemi K et al. Epigenetically altered miR-193b targets cyclin D1 in prostate cancer.
20 Kilpeläinen T et al. The Finnish prostate cancer screening trial: analyses on the screening failures.
21 Kääriäinen M et al. Utilization of Three-Dimensional Computer-Aided Preoperative Virtual Planning and Manufacturing in Maxillary and Mandibular Reconstruction with a Microvascular Fibula Flap.
22 Laitinen V et al. Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer.
23 Lehto U-M et al. Eturauhassyöpäpotilaan puolisokin tarvitsee tukea.
24 Murtola TJ et al. Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin.
25 Ojala H et al. Elämänlaatu koetaan yksilöllisesti .
26 Oksala N, Puska P. Utilisation of validated risk prediction algorithms and wearable and automated systems may help to prevent serious adverse events.
27 Oksala N et al. Kindlin 3 (FERMT3) is associated with unstable atherosclerotic plaques, anti-inflammatory type II macrophages and upregulation of beta-2 integrins in all major arterial beds.
28 Osman NI et al. Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH.
29 Pashayan N et al. Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC.
30 Pöyhönen R et al. Non-iatrogenic civilian vascular trauma in a well-defined geographical region in Finland.
31 Raitoharju E et al. MicroRNAs in the atherosclerotic plaque .
32 Riikonen J, Kaipia A. Recent developments in minimally invasive radical prostatectomy.
33 Ryödi E et al. Cancer Incidence and Mortality in Patients Treated Either With RAI or Thyroidectomy for Hyperthyroidism.
34 Ryödi E et al. Cardiovascular morbidity and mortality in surgically treated hyperthyroidism - a nation-wide cohort study with a long-term follow-up.
35 Saad F et al. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
36 Saarimäki L et al. Family history in the Finnish Prostate Cancer Screening Trial.
37 Scaravilli M et al. MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2.
38 Sibolt G et al. Severe cerebral white matter lesions in ischemic stroke patients are associated with less time spent at home and early institutionalization.
39 Szulkin R et al. Genome-Wide Association Study of Prostate Cancer-Specific Survival.
40 Szulkin R et al. Prediction of individual genetic risk to prostate cancer using a polygenic score.
41 Thomsen FB et al. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study.
42 Isola J et al. Length of prostate biopsies is not necessarily compromised by pooling multiple cores in one paraffin block: an observational study.
43 Turpeinen H et al. A genome-wide expression quantitative trait loci analysis of proprotein convertase subtilisin/kexin enzymes identifies a novel regulatory gene variant for FURIN expression and blood pressure.
44 Umbehr M et al. Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4?ng?ml(-1), normal DRE and negative for prostate cancer.
45 Uurto I et al. Muraglitazar-eluting bioabsorbable vascular stent inhibits neointimal hyperplasia in porcine iliac arteries.
46 Veitonmäki T et al. Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the finnish prostate cancer screening trial.
47 Violette PD et al. Decision aids for localized prostate cancer treatment choice: Systematic review and meta-analysis.
48 Wirth M et al. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
49 Yen AM et al. Prostate cancer screening using risk stratification based on a multi-state model of genetic variants.
50 Ylipää A et al. Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer.

Julkaisutietokanta 30.11.2016 Publications Data Base 30.11.2016